— Know what they know.
Not Investment Advice

TFX NYSE

Teleflex Incorporated
1W: +5.6% 1M: +12.2% 3M: +2.0% YTD: +11.9% 1Y: +3.8% 3Y: -25.0% 5Y: -60.8%
$138.69
+1.89 (+1.38%)
After Hours: $138.70 (+0.01, +0.01%)
Weekly Expected Move ±4.1%
$125 $131 $136 $142 $148
NYSE · Healthcare · Medical - Instruments & Supplies · Tech Score Strong Buy · Power 71 · $5.8B mcap · 42M float · 1.48% daily turnover · Short 72% of daily vol
Credit Risk of going bust: higher than 52% of companies Debt: 33.1% of company value Bonds: $146.4M held by 149 funds, 136 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $5.04 (down 96%), Teleflex Incorporated would be worth roughly what it owes.
Total debt $2.87B against a stock market value of $5.80B.
Distance to default 4.95 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.45B (short-term plus half of long-term), stock volatility 39.9%; Altman Z 1.98. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.8B
52W Range100.18-145
Volume682,906
Avg Volume624,156
Beta0.83
Dividend$1.36
Analyst Ratings
16 Buy 13 Hold 0 Sell
Consensus Buy
Company Info
CEOJason Weidman
Employees15,500
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date1980-03-17
550 East Swedesford Road
Wayne, PA 19087-1603
US
610 225 6800
About Teleflex Incorporated

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

Recent Insider Trades

NameTypeSharesPriceDate
Salmon Sean A-Award 674 — 2026-09-08
Salmon Sean A-Award 4,444 $137.00 2026-09-08
Salmon Sean 0 — 2026-09-08
Weidman Jason R. A-Award 53,983 — 2026-06-08
Weidman Jason R. A-Award 26,071 $131.74 2026-06-08

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms